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A commentary on
Three difficult cases: the challenge of
autoimmunity, immunodeficiency and
recurrent infections in patients with
Good’s syndrome
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SY, Cooper SM, Venning VA. Br J Dermatol
(2014). doi:10.1111/ bjd.13293
Good syndrome (GS), which is classi-
cally defined as the triad of thymoma,
immunodeficiency, and hypogammaglob-
ulinemia, was first characterized by Robert
Alan Good, a pioneer in the field of
immunodeficiency diseases, who recog-
nized the crucial role that the thymus plays
in the development of the immune system
(1). The definition of this entity remains
vague, in part because of the protean
immunological manifestations of thymic
epithelial neoplasms. How the thymus
influences the precise balance of immune
reactivity that is so critical to both host-
defense and self-tolerance remains to be
fully understood. Accordingly, immuno-
logic manifestations because of thymic
epithelial tumors can range from noth-
ing to severe autoimmunity, immunode-
ficiency, or both, the spectrum of which
is broad and patient-specific (Table 1).
Further, patients may have opportunistic
infection without gross immunologic lab
abnormalities (2), and conversely,may have
relatively few problems, despite an abnor-
mal immune profile (3). Nevertheless, we
can look to the immunology and infec-
tious complications in individual patients,
to identify where their immune defects are
most concentrated and how to go about
treating them.
The critical role that the thymus
plays in T cell education likely explains
the observation of coincident autoim-
munity and immunodeficiency in thy-
moma, reflecting T cells that are both
over-reactive to self and under-responsive
to pathogens. The importance of the
T cell in directing B cell responses
is also apparent in the immunopathol-
ogy of thymoma. Consistent with T
cell immunodeficiency, patients with thy-
moma can develop pneumocystis pneu-
monia, cytomegalovirus, mucocutaneous
candidiasis, varicella zoster reactivation
(both localized and systemic), Kaposi’s sar-
coma, and progressive multifocal leukoen-
cephalopathy, cryptococcosis, and non-
tuberculous mycobacteria (2, 4, 5). Under-
scoring the B cell component of this
disease, the cardinal manifestation of
GS is hypogammaglobulinemia. In fact,
the most prominent clinical character-
istics of GS includes an increased sus-
ceptibility to sinopulmonary bacterial
infections with encapsulated organisms
(Haemophilus influenza and Streptococ-
cus pneumonia), which is clearly associ-
ated with hypogammaglobulinemia. Even
outside classical GS, a tendency toward
B cell dysfunction is apparent in the
observation that anti-acetylcholine recep-
tor autoantibody-associated myasthenia
gravis is the most frequent autoimmune
complication of thymoma (6). B cell
lymphopenia is also common and in
some cases has even led to the ini-
tial diagnosis of thymoma (7, Allergy
and Asthma Proceedings). Together, these
observations underscore the complex
interrelatedness of T and B lymphocyte
biology.
Another potential mechanism of infec-
tion susceptibility is presence of anti-
cytokine autoantibodies (2, 8–10). It is
clear that anti-cytokine autoantibodies are
an important and emerging mechanisms
of adult-onset immunodeficiency (11) and
can be responsible for severe opportunis-
tic infection in previously healthy adults
(12,13). Interestingly,mucocutaneous can-
didiasis has been seen in association with
anti-IL-17 and anti-IL-22 autoantibodies
in autoimmune polyendocrinopathy can-
didiasis ectodermal dystrophy (APECED)
syndrome (14, 15), caused by a Mendelian
deficiency of the autoimmune regulator
(AIRE) gene. AIRE is critical for the neg-
ative selection of autoreactive T cells in
the thymus (16) and likely explains much
of the profound and diverse autoimmune
phenomena that are typical of APECED.
This compelling link between autoimmu-
nity and immunodeficiency may also be
relevant to thymoma where defective AIRE
expression has been recognized (17), as has
a predisposition to mucocutaneous can-
didiasis in association with anti-IL-17 and
IL-22 autoantibodies (2, 14).
Immunological evaluation can
include an assessment of quantitative
immunoglobulins, as well as B and T lym-
phocyte subsets. If the clinical presentation
points to antibody deficiency, a vaccine
challenge may help evaluate the patient’s
ability to generate an appropriate humoral
response, which can be impaired even with
relatively normal IgG levels. Testing for
anti-cytokine autoantibodies is done in
specialized laboratories on a research basis.
Treatment of infection generally focuses
on targeted antimicrobial therapy. In the
case of recurrent sinopulmonary infections
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Table 1 | Immunologic abnormalities reported in thymoma.
Laboratory
features
Abnormality/
activity
Clinical
associations
Management Comments
LYMPHOCYTE SUBSETS
CD20+ B cells Decreased in
peripheral blood (2, 3)
Immunodeficiency Consider vaccine challenge to
evaluate ability to mount
antibody response
May be independent of
hypogammaglobulinemia
CD20+/CD27+
memory B cells
Decreased in
peripheral blood (2)
Unknown, often in
setting of total B cell
lymphopenia
As above As above
CD4+ T cells May be increased or
decreased in
peripheral blood (2, 3)
Elevated levels
associated with
autoimmunity
Therapy targeting clinical
manifestations
CMV encephalitis reported in the
presence of normal CD4+ T cell counts
(18)
CD8+ T cells May be increased or
decreased in
peripheral blood (2, 3)
Elevated levels
associated with
immunodeficiency
Therapy directed at clinical
manifestations; consider
secondary prophylaxis if history
of opportunistic infection
The accumulation of CD8+CD45RA+ T
cells can be used to monitor clinical
stages of immunodeficiency in thymoma
(19)
CD16+ or CD56+
NK cells
May be increased or
decreased in
peripheral blood (2, 3)
Unknown No specific therapy indicated Low or dysfunctional NK cells associated
with herpes virus infection
IMMUNOGLOBULINS (Ig)
IgG May be increased or
decreased in
peripheral blood (2, 3)
Recurrent bacterial
sinopulmonary
infections
If there is an inadequate
antibody response, or history of
severe or recurrent infection,
immunoglobulin replacement
therapy may be started (18)
Even if immunoglobulins normal or high,
consider vaccine challenge to evaluate
ability to mount antibody response,
particularly if history of severe or
recurrent infections (18)
IgA May be increased or
decreased in
peripheral blood (2, 3)
Unknown No specific therapy indicated None
IgM May be increased or
decreased in
peripheral blood (2, 3)
Unknown No specific therapy indicated None
ANTI-CYTOKINE AUTOANTIBODIES
Anti-IFNα Prevents
IFNα-induced pSTAT-1
and pSTAT-4 in vitro (2)
Unknown IFNα given to one patient with
disseminated zoster
Associated with one case of disseminated
severe varicella zoster infection in patient
without thymoma; thymoma patients may
have disseminated or localized varicella
reactivation
Anti-IFNβ Prevents IFNβ-induced
pSTAT-1 in vitro (2)
Unknown No specific therapy indicated One case of activating anti-IFNβ
autoantibodies (unpublished data)
Anti-IFNω Prevents
IFNω-induced pSTAT-1
(unpublished data)
Unknown No specific therapy indicated Autoantibodies against type I IFNs
common in APECED suggesting etiologic
role of gene AIRE for origin of some
anti-cytokine autoantibodies
Anti-IL-1α Prevents PHA-induced
IFNγ production by T
cells (2)
Unknown No specific therapy indicated Can be seen in normal hosts (12)
(Continued)
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Table 1 | Continued
Laboratory
features
Abnormality/
activity
Clinical
associations
Management Comments
Anti-IL-12p70 Prevents IL-12-induced
pSTAT-4 in vitro;
prevented
IL-12-induced IFNγ
in vitro (2)
Unknown Targeted anti-infectives Associated with one case of disseminated
Burkholderia gladioli infection in patient
without thymoma
Anti-12p35 Same as effects seen
with anti-IL-12p70
autoantibodies
Unknown No specific therapy indicated None
Anti-IL-12p40 Same as effects seen
with anti-IL-12p70
Unknown No specific therapy indicated The p40 subunit is common to IL-23,
raising possibility for activity beyond
neutralization of IL-12
IL-17A or
anti-IL-17F
Prevents IL-17-induced
IL-6 production in HFF
cells (2)
CMC (14) Topical or systemic antifungals Associated with CMC in APECED
syndrome (14); may become
treatment-refractory
IL-22 Not assessed CMC (14) Topical or systemic antifungals Associated with CMC in APECED
syndrome; IL-22+/IL-17− cells protect
epithelial surfaces and show skin-homing
properties, which may explain the
mucocutaneous focus of the
candidiasis (14)
TNFα Not assessed (2) Unknown Unknown Unknown
NK, natural killer; IFN, interferon; APECED, autoimmune polyendocrinopathy candidiasis ectodermal dystrophy; AIRE, autoimmune regulator; IL, interleukin; CMC,
chronic mucocutaneous candidiasis; TNFα, tumor necrosis factor alpha.
associated with hypogammaglobulinemia,
intravenous immunoglobulin (IVIg) can
be an effective prophylactic measure. IVIg
has also been used to augment the immune
response in the case of CMV infection
(5). It can also be effective in treat-
ing anti-acetylcholine receptor-associated
myasthenia gravis, although the mecha-
nistic explanation for this benefit remains
elusive. Secondary prophylaxis could be
considered in patients under certain cir-
cumstances such as those who have had
pneumocystis pneumonia.
A better understanding of the under-
lying immunological defects in thymoma
will enhance therapeutic options, such as
primary prophylaxis or immunomodula-
tion. Furthermore, despite the focality of
their primary immunologic lesion (the
neoplastic thymic epithelial cells), patients
with thymoma can demonstrate fascinat-
ing clinical overlaps with many other dis-
eases, from rheumatologic, hematologic,
and pulmonary disorders, to primary
and congenital immunodeficiency, and
far beyond. Thus, understanding thy-
moma, as Dr. Good so astutely recog-
nized in decades past, will provide an
important opportunity that should not
be missed, to improve care of these
complex patients, and to shed light
on fundamental principals of human
immunology.
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